Northwest Biotherapeutics (NWBO) Times Interest Earned (2010 - 2026)
Northwest Biotherapeutics' (NWBO) quarterly Times Interest Earned came in at -$4.65 in Q1 2026, up 57.0% year-on-year from -$2.96 in Q1 2025, and up 9.79% quarter-over-quarter from -$5.15 in Q4 2025.
Northwest Biotherapeutics (NWBO) Times Interest Earned (2010 - 2026) Analysis & Trends
Northwest Biotherapeutics' Times Interest Earned history runs 17 years deep, the most recent figure standing at -$4.65 for Q1 2026.
- On a quarterly basis, Times Interest Earned rose 57.0% year-over-year to -$4.65 in Q1 2026; TTM through Mar 2026 was -$5.82, a 12.14% decrease from a year earlier, with the FY2025 full-year figure at -$6.89, down 2813.62% from the prior year.
- Times Interest Earned rose to -$4.65 in Q1 2026 per NWBO's latest filing, from -$5.15 in the prior quarter.
- Across five years, Times Interest Earned topped out at $4.8 in Q4 2023 and bottomed at -$14.73 in Q2 2022.
- The 5-year median for Times Interest Earned is -$7.12 (2024), against an average of -$7.04.
- Biggest YoY gain for Times Interest Earned was 133.49% in 2023; the steepest drop was 5868.15% in 2023.
- Year by year, Times Interest Earned stood at -$14.34 in 2022, then jumped by 133.49% to $4.8 in 2023, then tumbled by 149.84% to -$2.39 in 2024, then sank by 115.26% to -$5.15 in 2025, then grew by 9.79% to -$4.65 in 2026.
- Per Business Quant, the three latest NWBO Times Interest Earned figures stand at -$4.65 (Q1 2026), -$5.15 (Q4 2025), and -$5.46 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -157.58 |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn | 3.88 |
| 10 | Northwest Biotherapeutics | 274.18 Mn | 272.39 Mn | - | -4.65 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.65 |
| Dec 31, 2025 | -5.15 |
| Sep 30, 2025 | -5.46 |
| Jun 30, 2025 | -1.48 |
| Mar 31, 2025 | -10.81 |
| Dec 31, 2024 | -2.39 |
| Sep 30, 2024 | -7.12 |
| Jun 30, 2024 | -10.27 |
| Mar 31, 2024 | -10.37 |
| Dec 31, 2023 | 4.80 |
| Sep 30, 2023 | -8.13 |
| Jun 30, 2023 | -10.43 |
| Mar 31, 2023 | -12.62 |
| Dec 31, 2022 | -14.34 |
| Sep 30, 2022 | -0.14 |
| Jun 30, 2022 | -14.73 |
| Mar 31, 2022 | -6.46 |
| Dec 31, 2021 | -9.26 |
| Sep 30, 2021 | -6.26 |
| Jun 30, 2021 | -15.37 |